This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management of oropharyngeal squamous carcinoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Squamous carcinomas of oropharynx

T1-2 N0 tumours of the oropharynx.

  • the choice of transoral surgical resection or primary radiotherapy should be offered
  • postoperative radiotherapy, with or without concomitant chemotherapy, should be considered if pathologically adverse risk factors have been identified.

Human pavillomavirus-related disease

  • if squamous cell carcinomas of the oropharynx then test using p16 immunohistochemistry
    • p16 test result should be considered as positive only if there is strong nuclear and cytoplasmic staining in more than 70% of tumour cells
    • high-risk HPV DNA or RNA in-situ hybridisation should be considered in all p16-positive cancers of the oropharynx to confirm HPV status.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.